Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Everolimus × Gynecologic × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 16 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 37 Genitourinary 32 Endocrine 20 Gastrointestinal 18 NET 15 Thoracic 9 Tumor-Agnostic 7 Lymphoid 5 CNS 5 Sarcoma 4 Other solid neoplasm 3 Other hematologic neoplasm 3 Myeloid 1 Gynecologic 1

Conditions

Endometrial Neoplasms 1 Breast Neoplasms 1

Interventions

Paclitaxel 166 Carboplatin 140 pembrolizumab 105 Bevacizumab 73 liposomal doxorubicin 56 Gemcitabine 46 Cisplatin 45 olaparib 44 Topotecan 38 Nivolumab 30 niraparib 29 Doxorubicin 27 Docetaxel 23 Cyclophosphamide 23 human papillomavirus vaccine, L1 type 16, 18 19 Drug Therapy 19 Pemetrexed 16 Injections 16 1-dodecylpyridoxal 16 mirvetuximab soravtansine 15 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15 lenvatinib 14 fludarabine 14 durvalumab 14 atezolizumab 14 avelumab 13 Irinotecan 13 Fulvestrant 13 Papillomavirus Vaccines 11 Oxaliplatin 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04188548 2025-06-04

EMBER

Eli Lilly and Company

Phase 1 Active not recruiting

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡